Clinical Trials Logo

Clinical Trial Summary

This study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments


Clinical Trial Description

This is an open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05124925
Study type Interventional
Source Novartis
Contact
Status Active, not recruiting
Phase Phase 2
Start date July 27, 2022
Completion date June 28, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT03839069 - Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis N/A
Completed NCT03865888 - Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome Phase 3
Terminated NCT04988087 - A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) Phase 2
Completed NCT02257957 - Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye Phase 3
Completed NCT01647737 - Green Tea Lozenges for the Management of Dry Mouth Phase 1/Phase 2
Recruiting NCT02450396 - Pregnancy and Medically Assisted Conception in Rare Diseases
Active, not recruiting NCT05350072 - Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome Phase 3
Recruiting NCT03816345 - Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Phase 1
Active, not recruiting NCT02132585 - Cross-sectional Study of Use of Speckle Method in Early Diagnosis of Cardiovascular Dysfunction N/A
Completed NCT01850979 - Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Phase 4
Recruiting NCT05349214 - Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome Phase 3